Biodegradable, elastomeric coatings with controlled anti-proliferative agent release for magnesium-based cardiovascular stents.

Vascular stent design continues to evolve to further improve the efficacy and minimize the risks associated with these devices. Drug-eluting coatings have been widely adopted and, more recently, biodegradable stents have been the focus of extensive evaluation. In this report, biodegradable elastomeric polyurethanes were synthesized and applied as drug-eluting coatings for a relatively new class of degradable vascular stents based on Mg. The dynamic degradation behavior, hemocompatibility and drug release were investigated for poly(carbonate urethane) urea (PCUU) and poly(ester urethane) urea (PEUU) coated magnesium alloy (AZ31) stents. Poly(lactic-co-glycolic acid) (PLGA) coated and bare stents were employed as control groups. The PCUU coating effectively slowed the Mg alloy corrosion in dynamic degradation testing compared to PEUU-coated, PLGA-coated and bare Mg alloy stents. This was confirmed by electron microscopy, energy-dispersive x-ray spectroscopy and magnesium ion release experiments. PCUU-coating of AZ31 was also associated with significantly reduced platelet adhesion in acute blood contact testing. Rat vascular smooth muscle cell (rSMC) proliferation was successfully inhibited when paclitaxel was released from pre-loaded PCUU coatings. The corrosion retardation, low thrombogenicity, drug loading capacity, and high elasticity make PCUU an attractive option for drug eluting coating on biodegradable metallic cardiovascular stents.

[1]  Haoming Song,et al.  Poly-l-lactic acid/amorphous calcium phosphate bioabsorbable stent causes less inflammation than poly-l-lactic acid stent in coronary arteries. , 2014, International journal of clinical and experimental medicine.

[2]  Patrick W Serruys,et al.  Fully Biodegradable Coronary Stents , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[3]  Michael S Sacks,et al.  Synthesis, characterization, and cytocompatibility of elastomeric, biodegradable poly(ester-urethane)ureas based on poly(caprolactone) and putrescine. , 2002, Journal of biomedical materials research.

[4]  Shen‐guo Wang,et al.  Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin. , 2003, Biomaterials.

[5]  Bao-ping Zhang,et al.  Improved blood compatibility of Mg-1.0Zn-1.0Ca alloy by micro-arc oxidation. , 2011, Journal of biomedical materials research. Part A.

[6]  H. Liu,et al.  A Study on Factors Affecting the Degradation of Magnesium and a Magnesium-Yttrium Alloy for Biomedical Applications , 2013, PloS one.

[7]  P. Serruys,et al.  Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same? , 2007, Circulation.

[8]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[9]  R. Misra,et al.  Biomaterials , 2008 .

[10]  K. Tobita,et al.  The effect of polymer degradation time on functional outcomes of temporary elastic patch support in ischemic cardiomyopathy. , 2013, Biomaterials.

[11]  T. narayanan,et al.  Strategies to improve the corrosion resistance of microarc oxidation (MAO) coated magnesium alloys for degradable implants: Prospects and challenges , 2014 .

[12]  Tim Woodfield,et al.  Magnesium alloys: predicting in vivo corrosion with in vitro immersion testing. , 2012, Journal of biomedical materials research. Part B, Applied biomaterials.

[13]  Hongfan Sun,et al.  The prevention of restenosis in vivo with a VEGF gene and paclitaxel co-eluting stent. , 2013, Biomaterials.

[14]  R. Waksman,et al.  Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  J. Goudevenos,et al.  Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited. , 2009, JACC. Cardiovascular interventions.

[16]  M. Schulz,et al.  In Vivo and In Vitro Degradation Behavior of Magnesium Alloys as Biomaterials , 2012 .

[17]  W. Wagner,et al.  Synthesis, characterization, and paclitaxel release from a biodegradable, elastomeric, poly(ester urethane)urea bearing phosphorylcholine groups for reduced thrombogenicity. , 2012, Biomacromolecules.

[18]  I. Rodríguez,et al.  A novel nanostructured poly(lactic-co-glycolic-acid)-multi-walled carbon nanotube composite for blood-contacting applications: thrombogenicity studies. , 2009, Acta biomaterialia.

[19]  Michael P. Robich,et al.  Drug-eluting stent coatings , 2012 .

[20]  P. Chu,et al.  Degradation susceptibility of surgical magnesium alloy in artificial biological fluid containing albumin , 2007 .

[21]  M. Maitz,et al.  A surface-eroding poly(1,3-trimethylene carbonate) coating for fully biodegradable magnesium-based stent applications: toward better biofunction, biodegradation and biocompatibility. , 2013, Acta biomaterialia.

[22]  F. Eberli,et al.  Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial , 2011, The Lancet.

[23]  Yufeng Zheng,et al.  In vitro corrosion and biocompatibility of binary magnesium alloys. , 2009, Biomaterials.

[24]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[25]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[26]  Lakeshia J Taite,et al.  Nitric oxide-releasing polyurethane-PEG copolymer containing the YIGSR peptide promotes endothelialization with decreased platelet adhesion. , 2008, Journal of biomedical materials research. Part B, Applied biomaterials.

[27]  A. Boccaccini,et al.  Electrochemical investigations of magnesium in DMEM with biodegradable polycaprolactone coating as corrosion barrier , 2013 .

[28]  Y. Ikada,et al.  Simple method for platelet counting. , 1995, Biomaterials.

[29]  Nicholas A Peppas,et al.  Recent advances in drug eluting stents. , 2013, International journal of pharmaceutics.

[30]  N. Kawazoe,et al.  In vitro evaluation of biodegradation of poly(lactic-co-glycolic acid) sponges. , 2008, Biomaterials.

[31]  Raimund Erbel,et al.  Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial , 2013, The Lancet.

[32]  X. Mo,et al.  Biodegradable poly(ester urethane)urea elastomers with variable amino content for subsequent functionalization with phosphorylcholine. , 2014, Acta biomaterialia.

[33]  Feng Zhao,et al.  Metallic zinc exhibits optimal biocompatibility for bioabsorbable endovascular stents. , 2015, Materials science & engineering. C, Materials for biological applications.

[34]  J. Guan,et al.  Tailoring the degradation kinetics of poly(ester carbonate urethane)urea thermoplastic elastomers for tissue engineering scaffolds. , 2010, Biomaterials.

[35]  Song Li,et al.  Antithrombogenic Modification of Small-Diameter Microfibrous Vascular Grafts , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[36]  Soo Teik Lim,et al.  Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial , 2016, The Lancet.

[37]  Yingwei Song,et al.  Biodegradable behaviors of AZ31 magnesium alloy in simulated body fluid , 2009 .

[38]  G. Fu,et al.  In situ endothelialization of intravascular stents coated with an anti-CD34 antibody functionalized heparin-collagen multilayer. , 2010, Biomaterials.

[39]  John A Ormiston,et al.  Bioabsorbable coronary stents. , 2009, Circulation. Cardiovascular interventions.

[40]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[41]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[42]  A. Wear.  CIRCULATION , 1964, The Lancet.

[43]  Subbu S Venkatraman,et al.  The effect of topography of polymer surfaces on platelet adhesion. , 2010, Biomaterials.

[44]  이화영.  X , 1960, Chinese Plants Names Index 2000-2009.

[45]  Andrew G. Glen,et al.  APPL , 2001 .

[46]  W. Ferrando.  Review of corrosion and corrosion control of magnesium alloys and composites , 1989 .

[47]  V. Shanov,et al.  Flow-induced corrosion behavior of absorbable magnesium-based stents. , 2014, Acta biomaterialia.

[48]  N. Krott,et al.  A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. , 2006, Journal of the American College of Cardiology.

[49]  Keith D K Luk,et al.  A biodegradable polymer-based coating to control the performance of magnesium alloy orthopaedic implants. , 2010, Biomaterials.

[50]  E. Rocca,et al.  Corrosion resistance of plasma-anodized AZ91D magnesium alloy by electrochemical methods , 2007 .

[51]  Dongwon Lee,et al.  Reduction of inflammatory responses and enhancement of extracellular matrix formation by vanillin-incorporated poly(lactic-co-glycolic acid) scaffolds. , 2012, Tissue engineering. Part A.

[52]  Frank Witte,et al.  The history of biodegradable magnesium implants: a review. , 2010, Acta biomaterialia.

[53]  E. Topp,et al.  Physical properties of PLGA films during polymer degradation , 2009 .

[54]  장윤희,et al.  Y. , 2003, Industrial and Labor Relations Terms.

[55]  Yoshinobu Onuma,et al.  Bioresorbable scaffolds: rationale, current status, challenges, and future. , 2014, European heart journal.

[56]  K. Neoh,et al.  The effect of VEGF functionalization of titanium on endothelial cells in vitro. , 2010, Biomaterials.

[57]  Z. Shi,et al.  In vitro biodegradation behavior of magnesium and magnesium alloy. , 2011, Journal of biomedical materials research. Part B, Applied biomaterials.

[58]  G. Biondi-Zoccai,et al.  Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®) , 2008, Vascular health and risk management.

[59]  Yunchang Xin,et al.  Influence of aggressive ions on the degradation behavior of biomedical magnesium alloy in physiological environment. , 2008, Acta biomaterialia.

[60]  Sriramakamal Jonnalagadda,et al.  Predictors of glass transition in the biodegradable poly‐lactide and poly‐lactide‐co‐glycolide polymers , 2006 .

[61]  Jeremy Goldman,et al.  Zinc Exhibits Ideal Physiological Corrosion Behavior for Bioabsorbable Stents , 2013, Advanced materials.

[62]  Kazuhiko Ishihara,et al.  Surface modification of a biodegradable magnesium alloy with phosphorylcholine (PC) and sulfobetaine (SB) functional macromolecules for reduced thrombogenicity and acute corrosion resistance. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[63]  Alexander M Seifalian,et al.  Evolution of covered stents in the contemporary era: clinical application, materials and manufacturing strategies using nanotechnology. , 2013, Biotechnology advances.

[64]  N. Barakat,et al.  Influence of electrospinning and dip-coating techniques on the degradation and cytocompatibility of Mg-based alloy , 2013 .

[65]  A. Heyn,et al.  Short and long term degradation behaviour of Mg–1Ca magnesium alloys and protective coatings based on plasma‐chemical oxidation and biodegradable polymer coating in synthetic body fluid , 2013 .

[66]  Andreas Lendlein,et al.  Degradable, Multifunctional Cardiovascular Implants: Challenges and Hurdles , 2010 .

[67]  Ying Chen,et al.  Interaction between a high purity magnesium surface and PCL and PLA coatings during dynamic degradation , 2011, Biomedical materials.

[68]  Jeremy Goldman,et al.  A simplified in vivo approach for evaluating the bioabsorbable behavior of candidate stent materials. , 2012, Journal of biomedical materials research. Part B, Applied biomaterials.